Indefinite Delivery Contract 75D30125D20401
Award Date
12/31/24
Last Date to Order
2/28/26
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide adult influenza vaccines for the 2024-2025 season. The $13,916,000 multiple award IDC has a period of performance through February 28, 2025. The contract does not have any set-aside designations. Glaxosmithkline will likely provide the vaccines from its facilities in North Carolina to support the CDC's immunization programs...
The federal contract IDV awarded to Glaxosmithkline, LLC is a $83,834,950 Indefinite Delivery Contract to provide a range of adult vaccines to the Centers for Disease Control and Prevention (CDC) for a period of performance through June 30, 2019. The single-award contract was issued without any set-aside designation. The contract aims to procure various pharmaceutical products and immunization services to support public health initiatives, including influenza vaccines, hepatitis vaccines,...
The federal contract IDV award SPE2DP18D0006 is a single-award indefinite delivery contract issued by the U.S. Department of Defense (DoD) Medical Supply Chain to the pharmaceutical company Glaxosmithkline, LLC. The contract, valued at a ceiling of $27,848,725.95, enables the DoD to order influenza virus vaccines and other pharmaceutical products from Glaxosmithkline, a foreign-owned for-profit organization, over the term of the agreement. Task orders issued under the IDV provide for the firm...
The Indefinite Delivery Contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh provides adult flu vaccines for the 2023-2024 period. Glaxosmithkline, LLC was awarded a multiple award contract with a potential value of $13.9 million to deliver flu vaccines through February 2028 under associated task orders or price lists. The solicitation aimed to procure adult flu vaccines to support the Centers for Disease Control and Prevention's...
The federal contract IDV award is for the procurement of pediatric flu vaccines by the Centers for Disease Control and Prevention (CDC) Pittsburgh, a civilian agency. The prime contractor is Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company that specializes in vaccines, antiviral medications, and other medical countermeasures. The contract has a ceiling value of $182,592,000.00 and a period of performance from December 31, 2024 to February 28, 2026. It is a multiple award,...
The indefinite delivery contract (IDV) with ID 75D30119D05108 was awarded to Glaxosmithkline, LLC by the Centers for Disease Control and Prevention (CDC) for the delivery of adult vaccines. The $112,644,450 multiple award contract, which does not have any set-aside designations, has a period of performance from July 1, 2019 to June 30, 2024. Under this IDV, Glaxosmithkline provides a range of pharmaceutical goods and services as the prime contractor, including influenza virus and hepatitis...
The federal contract IDV being summarized is a multiple award Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc. for the delivery of adult influenza vaccines for the 2024-2025 flu season. The $215,741,000 IDC covers a range of influenza vaccine products and presentations, including multi-dose vials, pre-filled syringes, and specialized formulations for different age groups. Seqirus, a foreign-owned for-profit manufacturer,...
The Centers for Disease Control and Prevention awarded a single-award indefinite delivery contract to Glaxosmithkline, LLC to procure adult influenza vaccines. The contract has a potential value of $13 million and a period of performance from December 2020 through February 2022. The original solicitation sought proposals for the purchase of influenza vaccines for individuals aged 19 years and older to support immunization programs under Section 317(j) of the Public Health Service Act. Offerors...
The federal contract IDV award to Glaxosmithkline, LLC is for the supply of pediatric influenza vaccines to the Centers for Disease Control and Prevention (CDC) for distribution to immunization programs under the Section 317(j) Public Health Service Act and Vaccines for Children program. The single-award contract has a ceiling value of $161,025,000 and a period of performance from December 31, 2020 to February 28, 2022. The contract was issued in response to a CDC solicitation for a minimum...
The federal contract IDV award SPE2DP24D0005 is a single award indefinite delivery contract with a ceiling value of $2,327,325.00, awarded by the Defense Logistics Agency's Medical Supply Chain to the prime contractor Glaxosmithkline, LLC, doing business as Glaxosmithkline. The contract is for the delivery of influenza virus vaccines, with a period of performance through March 12, 2025. A task order with award ID SPE2DP24D0005|SPE2DP24F3249 was issued on March 14, 2024 for a firm fixed price...